Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trial

{ 'indexed': {'date-parts': [[2024, 3, 13]], 'date-time': '2024-03-13T18:30:13Z', 'timestamp': 1710354613699}, 'reference-count': 31, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 7, 1]], 'date-time': '2022-07-01T00:00:00Z', 'timestamp': 1656633600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 3, 15]], 'date-time': '2022-03-15T00:00:00Z', 'timestamp': 1647302400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 7]]}, 'DOI': '10.1016/j.lana.2022.100243', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T12:27:40Z', 'timestamp': 1648729660000}, 'page': '100243', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 7, 'title': 'Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 ' '(COPE – Coalition V): A double-blind, multicentre, randomised, controlled trial', 'prefix': '10.1016', 'volume': '11', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-3073-6890', 'authenticated-orcid': False, 'given': 'Álvaro', 'family': 'Avezum', 'sequence': 'first', 'affiliation': []}, {'given': 'Gustavo B F', 'family': 'Oliveira', 'sequence': 'additional', 'affiliation': []}, {'given': 'Haliton', 'family': 'Oliveira', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4004-1320', 'authenticated-orcid': False, 'given': 'Rosa C', 'family': 'Lucchetta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valéria F A', 'family': 'Pereira', 'sequence': 'additional', 'affiliation': []}, {'given': 'André L', 'family': 'Dabarian', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ricardo', 'family': 'D´O Vieira', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniel V', 'family': 'Silva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Adrian P M', 'family': 'Kormann', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre P', 'family': 'Tognon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ricardo', 'family': 'De Gasperi', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5998-5364', 'authenticated-orcid': False, 'given': 'Mauro E', 'family': 'Hernandes', 'sequence': 'additional', 'affiliation': []}, {'given': 'Audes D M', 'family': 'Feitosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Agnaldo', 'family': 'Piscopo', 'sequence': 'additional', 'affiliation': []}, {'given': 'André S', 'family': 'Souza', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlos H', 'family': 'Miguel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Vinicius O', 'family': 'Nogueira', 'sequence': 'additional', 'affiliation': []}, {'given': 'César', 'family': 'Minelli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlos C', 'family': 'Magalhães', 'sequence': 'additional', 'affiliation': []}, {'given': 'Karen M L', 'family': 'Morejon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Letícia S', 'family': 'Bicudo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Germano E C', 'family': 'Souza', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marco A M', 'family': 'Gomes', 'sequence': 'additional', 'affiliation': []}, {'given': 'José J F Raposo', 'family': 'Fo', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5535-6288', 'authenticated-orcid': False, 'given': 'Alexandre V', 'family': 'Schwarzbold', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre', 'family': 'Zilli', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roberto B', 'family': 'Amazonas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Frederico R', 'family': 'Moreira', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7227-2863', 'authenticated-orcid': False, 'given': 'Lucas B O', 'family': 'Alves', 'sequence': 'additional', 'affiliation': []}, {'given': 'Silvia R L', 'family': 'Assis', 'sequence': 'additional', 'affiliation': []}, {'given': 'Precil D M M', 'family': 'Neves', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-7956-1606', 'authenticated-orcid': False, 'given': 'Jessica Y', 'family': 'Matuoka', 'sequence': 'additional', 'affiliation': []}, {'given': 'Icaro', 'family': 'Boszczowski', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniela G M', 'family': 'Catarino', 'sequence': 'additional', 'affiliation': []}, {'given': 'Viviane C', 'family': 'Veiga', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luciano C P', 'family': 'Azevedo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Regis G', 'family': 'Rosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Renato D', 'family': 'Lopes', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre B', 'family': 'Cavalcanti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Otavio', 'family': 'Berwanger', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.lana.2022.100243_bib0001', 'series-title': 'WHO Coronavirus (COVID-19) Dashboard', 'year': '2022'}, { 'key': '10.1016/j.lana.2022.100243_bib0002', 'article-title': 'Impact of SARS-CoV-2 Delta variant on incubation, transmission settings ' 'and vaccine effectiveness: results from a nationwide case-control study ' 'in France', 'author': 'Grant', 'year': '2021', 'journal-title': 'Lancet Reg Health Eur'}, { 'key': '10.1016/j.lana.2022.100243_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '2126', 'DOI': '10.1016/S0140-6736(21)02758-6', 'article-title': 'Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic', 'volume': '398', 'author': 'Karim', 'year': '2021', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.lana.2022.100243_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '204', 'DOI': '10.1038/d41586-021-03619-8', 'article-title': "Beyond Omicron: what's next for COVID's viral evolution", 'volume': '600', 'author': 'Callaway', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '10.1016/j.lana.2022.100243_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '843', 'DOI': '10.1080/14787210.2020.1771181', 'article-title': 'Old and re-purposed drugs for the treatment of COVID-19', 'volume': '18', 'author': 'Jean', 'year': '2020', 'journal-title': 'Expert Rev Anti Infect Ther'}, { 'key': '10.1016/j.lana.2022.100243_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1056/NEJMoa2023184', 'article-title': 'Repurposed antiviral drugs for COVID-19-interim WHO solidarity trial ' 'results', 'volume': '384', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.lana.2022.100243_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARS-CoV-2 infection in vitro', 'volume': '6', 'author': 'Liu', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '10.1016/j.lana.2022.100243_bib0009', 'doi-asserted-by': 'crossref', 'first-page': '546', 'DOI': '10.3390/pathogens9070546', 'article-title': 'SARS-CoV-2, ACE2, and hydroxychloroquine: cardiovascular complications, ' 'therapeutics, and clinical readouts in the current settings', 'volume': '9', 'author': 'Kalra', 'year': '2020', 'journal-title': 'Pathogens'}, { 'key': '10.1016/j.lana.2022.100243_bib0010', 'doi-asserted-by': 'crossref', 'first-page': '623', 'DOI': '10.7326/M20-4207', 'article-title': 'Hydroxychloroquine in nonhospitalized adults with early COVID-19', 'volume': '173', 'author': 'Skipper', 'year': '2020', 'journal-title': 'Ann Intern Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0011', 'article-title': 'Hydroxychloroquine for early treatment of adults with mild coronavirus ' 'disease 2019: a randomized, controlled trial', 'author': 'Mitjà', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, { 'key': '10.1016/j.lana.2022.100243_bib0012', 'article-title': 'Chloroquine or hydroxychloroquine for prevention and treatment of ' 'COVID-19', 'author': 'Singh', 'year': '2021', 'journal-title': 'Cochrane Database Syst Rev'}, { 'key': '10.1016/j.lana.2022.100243_bib0013', 'article-title': 'Rationale and design of the COVID-19 outpatient prevention evaluation ' '(COPE) randomized clinical trial: hydroxychloroquine vs. placebo in ' 'non-hospitalized patients', 'author': 'Junior', 'year': '2022', 'journal-title': 'Arq Bras Cardiol'}, { 'key': '10.1016/j.lana.2022.100243_bib0014', 'unstructured': 'Lin T, Huang J. Generating Model Based Subgroup Analysis Using SAS ' 'Procedures. Proc. Pharm. SAS Users Gr. Conf. (PharmaSUG 2019) - SAS ' 'Inst. 2019. https://www.lexjansen.com/pharmasug/2009/?x=pharmasug2009. ' 'Accessed 17 November 2021.'}, { 'key': '10.1016/j.lana.2022.100243_bib0015', 'series-title': 'Survival Analysis: Models and Applications', 'author': 'Liu', 'year': '2012'}, { 'key': '10.1016/j.lana.2022.100243_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '132', 'DOI': '10.1177/1740774518823551', 'article-title': 'Assessing the impact of efficacy stopping rules on the error rates ' 'under the multi-arm multi-stage framework', 'volume': '16', 'author': 'Blenkinsop', 'year': '2019', 'journal-title': 'Clin Trials'}, { 'key': '10.1016/j.lana.2022.100243_bib0017', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2021.6468', 'article-title': 'Effect of early treatment with hydroxychloroquine or lopinavir and ' 'ritonavir on risk of hospitalization among patients with COVID-19', 'volume': '4', 'author': 'Reis', 'year': '2021', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.lana.2022.100243_bib0018', 'doi-asserted-by': 'crossref', 'first-page': 'E693', 'DOI': '10.9778/cmajo.20210069', 'article-title': 'Assessing the efficacy and safety of hydroxychloroquine as outpatient ' 'treatment of COVID-19: a randomized controlled trial', 'volume': '9', 'author': 'Schwartz', 'year': '2021', 'journal-title': 'C Open'}, { 'key': '10.1016/j.lana.2022.100243_bib0019', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.100773', 'article-title': 'Hydroxychloroquine with or without azithromycin for treatment of early ' 'SARS-CoV-2 infection among high-risk outpatient adults: a randomized ' 'clinical trial', 'volume': '33', 'author': 'Johnston', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'key': '10.1016/j.lana.2022.100243_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '417', 'DOI': '10.1056/NEJMoa2021801', 'article-title': 'A cluster-randomized trial of hydroxychloroquine for prevention of ' 'COVID-19', 'volume': '384', 'author': 'Mitjà', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0021', 'doi-asserted-by': 'crossref', 'first-page': '517', 'DOI': '10.1056/NEJMoa2016638', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for COVID-19', 'volume': '383', 'author': 'Boulware', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0022', 'doi-asserted-by': 'crossref', 'first-page': '344', 'DOI': '10.7326/M20-6519', 'article-title': 'Hydroxychloroquine as postexposure prophylaxis to prevent severe acute ' 'respiratory syndrome coronavirus 2 infection\xa0: a randomized trial', 'volume': '174', 'author': 'Barnabas', 'year': '2021', 'journal-title': 'Ann Intern Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0023', 'doi-asserted-by': 'crossref', 'unstructured': 'Abd-Elsalam S, Esmail ES, Khalaf M, et\xa0al. Hydroxychloroquine in the ' 'treatment of COVID-19: a multicenter randomized controlled study. Am J ' 'Trop Med Hyg; 103:1635–9.', 'DOI': '10.4269/ajtmh.20-0873'}, { 'key': '10.1016/j.lana.2022.100243_bib0024', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0257238', 'article-title': 'Hydroxychloroquine for the treatment of severe respiratory infection by ' 'COVID-19: a randomized controlled trial', 'volume': '16', 'author': 'Hernandez-Cardenas', 'year': '2021', 'journal-title': 'PLoS One'}, { 'key': '10.1016/j.lana.2022.100243_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '2165', 'DOI': '10.1001/jama.2020.22240', 'article-title': 'Effect of hydroxychloroquine on clinical status at 14 days in ' 'hospitalized patients with COVID-19', 'volume': '324', 'author': 'Self', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.lana.2022.100243_bib0026', 'doi-asserted-by': 'crossref', 'first-page': '2030', 'DOI': '10.1056/NEJMoa2022926', 'article-title': 'Effect of hydroxychloroquine in hospitalized patients with COVID-19', 'volume': '383', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0027', 'doi-asserted-by': 'crossref', 'first-page': '2041', 'DOI': '10.1056/NEJMoa2019014', 'article-title': 'Hydroxychloroquine with or without azithromycin in mild-to-moderate ' 'COVID-19', 'volume': '383', 'author': 'Cavalcanti', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0028', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pmed.1003252', 'article-title': 'COVID-19 prevention and treatment: a critical analysis of chloroquine ' 'and hydroxychloroquine clinical pharmacology', 'volume': '17', 'author': 'White', 'year': '2020', 'journal-title': 'PLOS Med'}, { 'key': '10.1016/j.lana.2022.100243_bib0029', 'unstructured': 'U.S Food and Drug Administration (FDA). US food and drug administration. ' 'memorandum explaining basis for revocation of emergency use ' 'authorization for emergency use of chloroquine phosphate and ' 'hydroxychloroquine sulfate. FDA site. 2020. ' 'https://www.fda.gov/media/138945/download. Accessed 17 November 2021.'}, { 'key': '10.1016/j.lana.2022.100243_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '411', 'DOI': '10.1080/14740338.2017.1269168', 'article-title': 'Hydroxychloroquine in systemic lupus erythematosus (SLE)', 'volume': '16', 'author': 'Ponticelli', 'year': '2017', 'journal-title': 'Expert Opin Drug Saf'}, { 'key': '10.1016/j.lana.2022.100243_bib0031', 'doi-asserted-by': 'crossref', 'first-page': '25', 'DOI': '10.2165/00002018-200427010-00003', 'article-title': 'Antimalarial drug toxicity', 'volume': '27', 'author': 'Taylor', 'year': '2004', 'journal-title': 'Drug Saf'}], 'container-title': 'The Lancet Regional Health - Americas', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2667193X22000606?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2667193X22000606?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 11, 19]], 'date-time': '2022-11-19T21:02:40Z', 'timestamp': 1668891760000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2667193X22000606'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7]]}, 'references-count': 31, 'alternative-id': ['S2667193X22000606'], 'URL': 'http://dx.doi.org/10.1016/j.lana.2022.100243', 'relation': {}, 'ISSN': ['2667-193X'], 'subject': ['Public Health, Environmental and Occupational Health', 'Internal Medicine', 'Health Policy'], 'container-title-short': 'The Lancet Regional Health - Americas', 'published': {'date-parts': [[2022, 7]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients ' 'with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, ' 'controlled trial', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'The Lancet Regional Health - Americas', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.lana.2022.100243', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, { 'value': 'https://doi.org/10.1016/j.lana.2022.100268', 'name': 'associatedlink', 'label': 'CrossRef DOI link to the associated document'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 The Authors. Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '100243'}